AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by analysts at Deutsche Bank in a research note issued on Tuesday, Digital Look reports. They currently have a GBX 6,800 ($88.85) target price on the biopharmaceutical company’s stock. Deutsche Bank’s price objective would indicate a potential upside of 5.43% from the stock’s previous close.
A number of other brokerages also recently weighed in on AZN. Liberum Capital reiterated a “hold” rating on shares of AstraZeneca in a report on Friday, March 29th. Jefferies Financial Group reiterated a “hold” rating on shares of AstraZeneca in a report on Thursday, March 14th. Goldman Sachs Group reiterated a “sell” rating on shares of AstraZeneca in a report on Monday, March 18th. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Monday, March 11th. Finally, Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Friday, March 29th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of GBX 6,497.06 ($84.90).
Shares of AZN stock opened at GBX 6,450 ($84.28) on Tuesday. AstraZeneca has a 1-year low of GBX 5,110 ($66.77) and a 1-year high of GBX 6,540 ($85.46). The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. The firm has a market cap of $84.61 billion and a PE ratio of 33.95.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.